

BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases

NCT07062055

Status	RECRUITING
Phase	Phase 2
Sponsor	Shandong Cancer Hospital and Institute
Enrollment	54 participants

Plain Language Summary

This study (called BRAVE) tests a combination of an immunotherapy drug (QL1706), a blood vessel-blocking drug (bevacizumab), and targeted radiation (SBRT) for people with advanced liver cancer that has spread into blood vessels or formed a small number of tumors in other organs.

****You may be eligible if...****

- You are between 18 and 70 years old
- You have advanced liver cancer (hepatocellular carcinoma, or HCC) confirmed by biopsy or clinical diagnosis
- Your cancer has grown into a major liver vein (portal vein tumor thrombus) or has spread to 5 or fewer tumors in 3 or fewer organs outside the liver
- Your liver function is relatively preserved (Child-Pugh class A or B, score 7 or less)
- You have at least one tumor that can be measured on imaging
- You have not received prior treatment for your liver cancer

****You may NOT be eligible if...****

- You have received prior treatment for liver cancer
- Your liver function is poor
- You have widespread cancer beyond the defined criteria

Talk to your doctor to see if this trial is right for you.

Key Eligibility Criteria

Inclusion (21)

- Male or female patients aged between 18 and 70 years.
- Unresectable HCC, BCLC Stage C according to the BCLC strategy-2025 update, with staging established via biopsy pathology and/or clinical diagnosis.
- Child-Pugh class A without clinically significant hepatic decompensation; Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Metastatic burden and SBRT eligibility
- Extrahepatic oligometastatic disease defined as d3 involved organs with d5 total metastatic lesions
- ... and 16 more (see full listing online)

Exclusion (32)

- Histopathological exclusions
- Mixed HCC subtypes: Fibrolamellar HCC or sarcomatoid HCC or cholangiocarcinoma components
- Curative local therapy candidacy
- Current candidacy for resection, liver transplant, or RFA

• RT infeasibility
<https://clinicaltrials.gov/study/NCT07062055>
and 27 more (see full listing online)

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.

Locations (1 total)

Shandong Cancer Hospital and Institute, Jinan, Shandong, China